MarketPulse

clinical-stage biotech

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Serina Therapeutics to Showcase POZ Platform at Roth Conference

Clinical-stage biotech Serina Therapeutics will present at 38th Annual Roth Conference on March 24, 2026, highlighting its proprietary POZ Platform technology and pipeline.
PFESERclinical-stage biotechParkinson's disease
The Motley FoolThe Motley Fool··Adé Hennis

Maze Therapeutics President Liquidates Full Position Ahead of Q4 Earnings

Maze Therapeutics president Harold Bernstein sold all 30,000 shares for $1.51M via pre-arranged trading plan, weeks before Q4 earnings report.
MAZEclinical-stage biotechearnings report
The Motley FoolThe Motley Fool··Jonathan Ponciano

Viking Therapeutics Lands $7M Investment as Obesity Drug Pipeline Gains Momentum

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.
CVXVKTXKRYSABVXPhase 3 trialsclinical-stage biotech
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Relmada Therapeutics to Unveil Q4 2025 Results Amid $160M Funding Boost

Relmada Therapeutics to report Q4 2025 results March 19, 2026, following $160M oversubscribed fundraise and Leerink Partners conference presentation.
RLMDclinical-stage biotechprivate placement
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dianthus to Unveil Phase 3 CIDP Trial Data as Claseprubart Nears Potential Breakthrough

Dianthus Therapeutics will present interim responder analysis from Phase 3 CAPTIVATE trial of claseprubart for CIDP treatment on March 9, 2026.
DNTHclinical-stage biotechPhase 3 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Ataibeckley Inc.

AtaiBeckley Secures FDA Nod for Phase 3 Depression Trial, Eyes 2029 Runway

AtaiBeckley advances psychedelic depression treatment to Phase 3 with $220.7M cash runway through early 2029, plus positive anxiety trial data.
ATAIPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nkarta to Present at Two Major Healthcare Investment Conferences in March

Nkarta to present at two major healthcare investor conferences in March 2026, showcasing updates on its engineered NK cell therapy pipeline for autoimmune diseases.
NKTXNK cell therapiesautoimmune diseases
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Hedge Fund Exits Protagonist Position Despite 120% Stock Surge

BVF Partners liquidated its $170M Protagonist stake despite 120% gains, likely due to changing risk profile as company awaits FDA decision on blood disorder treatment.
PTGXKYMRRVMDRVMDWclinical-stage biotechhedge fund liquidation